Clinical Trial Update: Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of extended-release levomilnacipran in adolescents with major depressive disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Levomilnacipran ER (levomilnacipran hydrochloride)

Snippet

Sponsor: Forest Laboratories | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2020-09-07